Gena Wang
Stock Analyst at Barclays
(2.18)
# 2,686
Out of 4,840 analysts
209
Total ratings
38.41%
Success rate
-4.81%
Average return
Main Sectors:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLDB Solid Biosciences | Maintains: Overweight | $15 → $10 | $3.04 | +228.95% | 7 | May 16, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Overweight | $9 → $5 | $0.45 | +1,003.51% | 4 | May 14, 2025 | |
| CLLS Cellectis | Maintains: Overweight | $5 → $4 | $1.46 | +173.97% | 4 | May 13, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $56 → $42 | $37.57 | +11.79% | 16 | May 9, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $45 → $38 | $3.42 | +1,011.11% | 2 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $56 → $42 | $47.86 | -12.24% | 15 | May 8, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $55 → $53 | $30.51 | +73.71% | 2 | May 8, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Equal-Weight | $8 → $11 | $10.79 | +1.95% | 10 | May 7, 2025 | |
| BEAM Beam Therapeutics | Maintains: Equal-Weight | $31 → $25 | $17.03 | +46.80% | 9 | May 7, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $45 → $40 | $26.76 | +49.48% | 9 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $8 | $5.00 | +60.00% | 11 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $57 | $30.35 | +87.81% | 2 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $4.66 | +565.24% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $26 | $9.33 | +178.82% | 7 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $435 → $467 | $446.00 | +4.71% | 16 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $1.65 | +81.82% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $3 → $4 | $3.58 | +11.73% | 8 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $329 | $290.10 | +13.41% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $58.11 | +48.00% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $226 → $203 | $38.35 | +429.34% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $50 | $9.07 | +451.27% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $35.08 | +130.90% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $51 | $33.32 | +53.06% | 9 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $28.76 | +226.84% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $11.22 | -19.79% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $12.03 | +107.81% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $5.09 | +253.98% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $8 | $8.16 | -1.96% | 1 | Nov 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $3.44 | +161.63% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $6.12 | +4,393.46% | 1 | Jan 6, 2017 |
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $15 → $10
Current: $3.04
Upside: +228.95%
Sangamo Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $9 → $5
Current: $0.45
Upside: +1,003.51%
Cellectis
May 13, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $1.46
Upside: +173.97%
CRISPR Therapeutics AG
May 9, 2025
Maintains: Equal-Weight
Price Target: $56 → $42
Current: $37.57
Upside: +11.79%
4D Molecular Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $38
Current: $3.42
Upside: +1,011.11%
PTC Therapeutics
May 8, 2025
Maintains: Equal-Weight
Price Target: $56 → $42
Current: $47.86
Upside: -12.24%
Cytokinetics
May 8, 2025
Maintains: Overweight
Price Target: $55 → $53
Current: $30.51
Upside: +73.71%
BioCryst Pharmaceuticals
May 7, 2025
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $10.79
Upside: +1.95%
Beam Therapeutics
May 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $17.03
Upside: +46.80%
Moderna
May 2, 2025
Maintains: Equal-Weight
Price Target: $45 → $40
Current: $26.76
Upside: +49.48%
Mar 31, 2025
Maintains: Overweight
Price Target: $40 → $8
Current: $5.00
Upside: +60.00%
Feb 28, 2025
Maintains: Overweight
Price Target: $63 → $57
Current: $30.35
Upside: +87.81%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $4.66
Upside: +565.24%
Feb 28, 2025
Maintains: Overweight
Price Target: $55 → $26
Current: $9.33
Upside: +178.82%
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $435 → $467
Current: $446.00
Upside: +4.71%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $1.65
Upside: +81.82%
Nov 15, 2024
Maintains: Underweight
Price Target: $3 → $4
Current: $3.58
Upside: +11.73%
Nov 1, 2024
Maintains: Overweight
Price Target: $295 → $329
Current: $290.10
Upside: +13.41%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $58.11
Upside: +48.00%
Aug 8, 2024
Maintains: Overweight
Price Target: $226 → $203
Current: $38.35
Upside: +429.34%
Aug 5, 2024
Maintains: Overweight
Price Target: $55 → $50
Current: $9.07
Upside: +451.27%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $35.08
Upside: +130.90%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $45 → $51
Current: $33.32
Upside: +53.06%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $28.76
Upside: +226.84%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $11.22
Upside: -19.79%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $12.03
Upside: +107.81%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $5.09
Upside: +253.98%
Nov 17, 2021
Maintains: Overweight
Price Target: $24 → $8
Current: $8.16
Upside: -1.96%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $3.44
Upside: +161.63%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $6.12
Upside: +4,393.46%